Long-term antipsychotic treatments and crossover studies in rats: Differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain

被引:139
作者
Pillai, Anilkumar [1 ]
Parikh, Vinay
Terry, Alvin V., Jr.
Mahadik, Sahebarao P.
机构
[1] Med Coll Georgia, Dept Psychiat & Hlth Behav, Augusta, GA 30912 USA
[2] Vet Affairs Med Ctr, Med Res Serv 242, Augusta, GA 30904 USA
[3] Univ Michigan, Dept Psychol, Ann Arbor, MI 48109 USA
[4] Univ Georgia, Med Coll Georgia, Coll Pharm, Program Clin & Expt Therapeut, Augusta, GA USA
关键词
oxidative stress; atypical antipsychotics; antioxidant enzymes; lipid peroxidation; brain;
D O I
10.1016/j.jpsychires.2006.01.011
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Short-term (< 45 days) treatment studies in rats have reported increased oxidative stress and oxidative (i.e., oxygen free radical-mediated) neural cell injury with typical antipsychotics such as haloperidol, but not with the atypicals such as clozapine, olanzapine or risperidone. However, now these and several other atypical antipsychotics that differ in their neurotransmitter receptor affinity profiles are being used for a long-term treatment of schizophrenia. Therefore, understanding of their long-term treatment effects on the expression of antioxidant enzymes and oxidative neural cell injury in rats may be important to explain the possible differential mechanisms underlying their long-term clinical and side effects profiles. The effect of 90 and 180 day exposure to haloperidol (HAL, 2 mg/kg/day), a representative typical antipsychotic was compared to exposure to chlorpromazine (CPZ, 10 mg/kg/day), ziprasidone (ZIP, 12 mg/kg/day), risperidone (RISP, 2.5 mg/kg/day), clozapine (CLOZ, 20 mg/kg/day) or olanzapine (OLZ, 10 mg/kg/day) on the expression of antioxidant defense enzymes and levels of lipid peroxidation in the rat brain. The drug-induced effects on various antioxidant defense enzymes; manganese-superoxide dismutase (MnSOD), copper-zinc superoxide dismutase (CuZnSOD) and catalase (CAT) were assessed by determination of their enzymatic activity and protein content. Immunohistochemical analysis was also carried out to assess the cellular levels of MnSOD and CuZnSOD and cellular morphology. The oxidative membrane damage was assessed by determination of levels of the lipid peroxidation product, hydroxyalkanals (HAEs) in the rat brain. Both 90 and 180 days of HAL treatment very significantly decreased the levels of MnSOD (50%) and CuZnSOD (80%) and increased the levels of HAEs compared to vehicle treatment. Smaller reduction was found in CAT (25%) and no change in the glutathione peroxidase (GSHPx). The levels of enzymatic activity correlated generally well with the levels of enzyme protein indicating that the changes were in the expression of net protein. Though atypical antipsychotics like ZIP, RISP and OLZ did not show any change in the HAEs levels up to 90 days, further treatment up to 180 days resulted in significantly increased levels of HAEs in CPZ, ZIP and RISP, but not in OLZ treated rats. Post-treatment with several atypical antipsychotics (OLZ = CLOZ > RISP) for 90 days after 90 day of HAL treatment significantly restored the HAL-induced loss in MnSOD and CuZnSOD activities and increase in lipid peroxidation products as well as cellular morphology. These data may be very helpful in planning long-term use as well as switch over of these antipsychotics for the management of schizophrenia. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:372 / 386
页数:15
相关论文
共 54 条
[1]   Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs [J].
Andersson, C ;
Hamer, RM ;
Lawler, CP ;
Mailman, RB ;
Lieberman, JA .
NEUROPSYCHOPHARMACOLOGY, 2002, 27 (02) :143-151
[2]   Chronic antipsychotic treatment selectively alters nerve growth factor and neuropeptide Y immunoreactivity and the distribution of choline acetyl transferase in rat brain regions [J].
Angelucci, F ;
Aloe, L ;
Gruber, SHM ;
Fiore, M ;
Mathé, AA .
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2000, 3 (01) :13-25
[3]   Protein thiol oxidation by haloperidol results in inhibition of mitochondrial complex I in brain regions: comparison with atypical antipsychotics [J].
Balijepalli, S ;
Kenchappa, RS ;
Boyd, MR ;
Ravindranath, V .
NEUROCHEMISTRY INTERNATIONAL, 2001, 38 (05) :425-435
[4]   Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol [J].
Beasley, CM ;
Dellva, MA ;
Tamura, RN ;
Morgenstern, H ;
Glazer, WM ;
Ferguson, K ;
Tollefson, GD .
BRITISH JOURNAL OF PSYCHIATRY, 1999, 174 :23-30
[5]   A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse [J].
Beasley, CM ;
Sutton, VK ;
Hamilton, SH ;
Walker, DJ ;
Dossenbach, M ;
Taylor, CC ;
Alaka, KJ ;
Bykowski, D ;
Tollefson, GD .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (06) :582-594
[6]  
Ben-Shachar D, 2004, INT REV NEUROBIOL, V59, P273
[7]   Mitochondrial enzymes in schizophrenia [J].
Bubber, P ;
Tang, JC ;
Haroutunian, V ;
Xu, H ;
Davis, KL ;
Blass, JP ;
Gibson, GE .
JOURNAL OF MOLECULAR NEUROSCIENCE, 2004, 24 (02) :315-321
[8]   Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha(1)-adrenergic and muscarinic receptors in vivo in rats [J].
Bymaster, FP ;
HemrickLuecke, SK ;
Perry, KW ;
Fuller, RW .
PSYCHOPHARMACOLOGY, 1996, 124 (1-2) :87-94
[9]  
CADET JL, 1989, ANN NY ACAD SCI, V570, P176
[10]   An integrated analysis of acute treatment-emergent extrapyramidal syndrome in patients with schizophrenia during olanzapine clinical trials: Comparisons with placebo, haloperidol, risperidone, or clozapine [J].
Carlson, CD ;
Cavazzoni, PA ;
Berg, PH ;
Wei, H ;
Beasley, CM ;
Kane, JM .
JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (08) :898-906